Month: September 2024

DelveInsight’s “Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Dilated Cardiomyopathy, offering comprehensive insights into the Dilated Cardiomyopathy revenue trends, prevalence, and treatment landscape. The report delves into key Dilated Cardiomyopathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dilated Cardiomyopathy therapies. Additionally, we cover the landscape of Dilated Cardiomyopathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dilated Cardiomyopathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dilated Cardiomyopathy space.

To Know in detail about the Dilated Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dilated Cardiomyopathy Market Forecast

Some of the key facts of the Dilated Cardiomyopathy Market Report: 

• The Dilated Cardiomyopathy market size was valued ~USD 463 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2023, the US had the largest market size for dilated cardiomyopathy, totaling approximately USD 329.4 million, surpassing the market sizes of the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

• In 2023, among the EU4 and the UK, Germany held the largest market for dilated cardiomyopathy at approximately USD 25.6 million, followed by France with around USD 20.8 million, while Spain had the smallest market, totaling about USD 14.4 million.

• In 2023, Japan’s total market size for dilated cardiomyopathy was approximately USD 34.2 million, with expectations of growth by 2034.

• Key Dilated Cardiomyopathy Companies: Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others

• Key Dilated Cardiomyopathy Therapies: Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), Ixmyelocel-T, COR-1, ARRY-371797, talfirastide, Ifetroban, and others.

• The Dilated Cardiomyopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dilated Cardiomyopathy pipeline products will significantly revolutionize the Dilated Cardiomyopathy market dynamics.

• DelveInsight’s estimates indicate that the total number of prevalent cases of dilated cardiomyopathy in the 7MM reached approximately 3,045,174 in 2023, with around 1,070,511 of those being diagnosed cases.

• DelveInsight’s analysis estimates that, in 2023, the US accounted for about 51.8% of the total diagnosed prevalent cases of dilated cardiomyopathy in the 7MM, with the EU4 and the UK making up approximately 37.6%, and Japan around 10.6%.

• DelveInsight’s epidemiology model for dilated cardiomyopathy estimates that, among the EU4 and the UK, Germany had the largest diagnosed prevalent population with around 103,096 cases in 2023, followed by France with approximately 83,529 diagnosed cases.

• In 2023, among the gender-specific diagnosed prevalent cases of dilated cardiomyopathy in the EU4 and the UK, males accounted for approximately 298,709 cases, while females made up around 103,829 cases.

Dilated Cardiomyopathy Overview

Dilated cardiomyopathy (DCM) is a condition where the heart’s chambers, particularly the left ventricle, become enlarged and weakened, reducing the heart’s ability to pump blood efficiently. This can lead to heart failure and other complications. DCM can be caused by genetic factors, infections, high blood pressure, or other underlying conditions. Symptoms may include fatigue, shortness of breath, and swelling in the legs. Treatment options focus on managing symptoms and may include medications, lifestyle changes, or devices to support heart function, and in severe cases, a heart transplant may be needed.

Get a Free sample for the Dilated Cardiomyopathy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/dilated-cardiomyopathy-market-forecast

Dilated Cardiomyopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dilated Cardiomyopathy Epidemiology Segmentation:

The Dilated Cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Dilated Cardiomyopathy in the 7MM

• Total Diagnosed Prevalent Cases of Dilated Cardiomyopathy in the 7MM

• Gender-specific Cases of Dilated Cardiomyopathy in the 7MM

• Familial and Non-familial Cases of Dilated Cardiomyopathy in the 7MM

Download the report to understand which factors are driving Dilated Cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Epidemiology Forecast

Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dilated Cardiomyopathy market or expected to get launched during the study period. The analysis covers Dilated Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dilated Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dilated Cardiomyopathy Therapies and Key Companies

• Danicamtiv (MYK-491): Bristol Myers Squibb

• BC007: Berlin Cures

• DYSCORBAN (ifetroban): Cumberland Pharmaceuticals

• Ixmyelocel-T: Vericel Corporation

• COR-1: Corimmun GmbH

• ARRY-371797: Pfizer

• talfirastide: Constant Therapeutics LLC

• Ifetroban: Cumberland Pharmaceuticals

Discover more about therapies set to grab major Dilated Cardiomyopathy market share @ Dilated Cardiomyopathy Treatment Landscape

Dilated Cardiomyopathy Market Strengths

• Increasing prevalence of drug or alcohol abuse and cardiac muscle infections, they are more likely to develop dilated cardiomyopathy in the 7MM and are anticipated to fuel the market growth.

• Recent advances in device therapies such as ICD, CRT, and surgical interventions have shown significant reductions in mortality and hospitalization rates among dilated cardiomyopathy patients.

Dilated Cardiomyopathy Market Opportunities

• The increasing prevalence and public awareness can provide an opportunity to enhance the genetic basis of dilated cardiomyopathy, genetic screening for at-risk individuals, and its management.

• Opportunities exist for pharmaceutical players to develop dilated cardiomyopathy therapies with improved efficacy, duration of action, and safety profiles, as well as to identify biomarkers.

Scope of the Dilated Cardiomyopathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dilated Cardiomyopathy Companies: Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others

• Key Dilated Cardiomyopathy Therapies: Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), Ixmyelocel-T, COR-1, ARRY-371797, talfirastide, Ifetroban, and others

• Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and Dilated Cardiomyopathy emerging therapies

• Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dilated Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Dilated Cardiomyopathy Market Access and Reimbursement 

To know more about Dilated Cardiomyopathy companies working in the treatment market, visit @ Dilated Cardiomyopathy Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Dilated Cardiomyopathy Market Report Introduction

2. Executive Summary for Dilated Cardiomyopathy

3. SWOT analysis of Dilated Cardiomyopathy

4. Dilated Cardiomyopathy Patient Share (%) Overview at a Glance

5. Dilated Cardiomyopathy Market Overview at a Glance

6. Dilated Cardiomyopathy Disease Background and Overview

7. Dilated Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Dilated Cardiomyopathy 

9. Dilated Cardiomyopathy Current Treatment and Medical Practices

10. Dilated Cardiomyopathy Unmet Needs

11. Dilated Cardiomyopathy Emerging Therapies

12. Dilated Cardiomyopathy Market Outlook

13. Country-Wise Dilated Cardiomyopathy Market Analysis (2020–2034)

14. Dilated Cardiomyopathy Market Access and Reimbursement of Therapies

15. Dilated Cardiomyopathy Market Drivers

16. Dilated Cardiomyopathy Market Barriers

17.  Dilated Cardiomyopathy Appendix

18. Dilated Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dilated Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun

DelveInsight’s “Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Down Syndrome, offering comprehensive insights into the Down Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Down Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Down Syndrome therapies. Additionally, we cover the landscape of Down Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Down Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Down Syndrome space.

To Know in detail about the Down Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Down Syndrome Market Forecast

Some of the key facts of the Down Syndrome Market Report: 

• The Down Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others

• Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others

• The Down Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Down Syndrome pipeline products will significantly revolutionize the Down Syndrome market dynamics.

• According to the DSAGSL organization (2022), around 400,000 Americans have been diagnosed with Down syndrome, and approximately 6,000 babies are born with the condition annually in the US.

• According to the Minnesota Health Department (2023), Down syndrome occurs in 1 in 800 to 1,000 live births and is the most prevalent genetic cause of developmental delay in the US. The department also stated that there are three types of Down syndrome: trisomy 21 (nondisjunction), which accounts for 95% of cases; translocation, which accounts for about 4%; and mosaicism, which represents around 1%.

• The Down Syndrome epidemiology based on gender analysed that males (54.5%) are affected slightly more than females (45.5%) with Down Syndrome

• According to Hoshi et al., the overall prevalence of Down syndrome births in Japan was 5.82 per 10,000 live births.

Down Syndrome Overview

Down syndrome is a genetic disorder caused by the presence of an extra copy of chromosome 21, also known as trisomy 21. This condition leads to developmental delays, intellectual disabilities, and characteristic physical features such as a flattened face, almond-shaped eyes, and a short neck. People with Down syndrome may also experience health issues like heart defects, hearing problems, and a higher risk of certain medical conditions. While there is no cure, early intervention, educational support, and medical care can help individuals with Down syndrome lead fulfilling lives.

Get a Free sample for the Down Syndrome Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/down-syndrome-market

Down Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Down Syndrome Epidemiology Segmentation:

The Down Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Diagnosed Prevalent Cases of Down Syndrome in the 7MM

• Type-specific Cases of Down Syndrome in the 7MM

• Gender-specific Cases of Down Syndrome in the 7MM

• Age-specific Cases of Down Syndrome in the 7MM

• Treated Cases of Down Syndrome in the 7MM

Download the report to understand which factors are driving Down Syndrome epidemiology trends @ Down Syndrome Epidemiology Forecast

Down Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Down Syndrome market or expected to get launched during the study period. The analysis covers Down Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Down Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Down Syndrome Therapies and Key Companies

• AEF0217: Aelis Farma

• ACI-24.060: AC Immune SA

• Donepezil HCl: Eisai Inc.

• E2020-Donepezil hydrochloride: Eisai Co., Ltd.

• RG1662: Hoffmann-La Roche

• Florbetaben (BAY94-9172): Life Molecular Imaging SA

• ACI-24.060: AC Immune SA

• Benralizumab: AstraZeneca

Discover more about therapies set to grab major Down Syndrome market share @ Down Syndrome Treatment Landscape

Down Syndrome Market Drivers

• Families, advocacy groups, and healthcare organizations offer strong support networks for individuals with Down syndrome, promoting awareness, research, and inclusive policies.

• Advances in medical care and technology have improved the early detection of Down syndrome during pregnancy, allowing for better medical management and support.

Down Syndrome Market Barriers

• Lack of approved medication for treating Down syndrome, provide pharma companies to bring novel therapies with first mover advantage.

• Technology advancements, such as assistive devices, communication aids, and accessible applications, offer opportunities to enhance communication and daily living skills for individuals with Down syndrome.

Scope of the Down Syndrome Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others

• Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others

• Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies

• Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Down Syndrome Unmet Needs, KOL’s views, Analyst’s views, Down Syndrome Market Access and Reimbursement 

To know more about Down Syndrome companies working in the treatment market, visit @ Down Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Down Syndrome Market Report Introduction

2. Executive Summary for Down Syndrome

3. SWOT analysis of Down Syndrome

4. Down Syndrome Patient Share (%) Overview at a Glance

5. Down Syndrome Market Overview at a Glance

6. Down Syndrome Disease Background and Overview

7. Down Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Down Syndrome 

9. Down Syndrome Current Treatment and Medical Practices

10. Down Syndrome Unmet Needs

11. Down Syndrome Emerging Therapies

12. Down Syndrome Market Outlook

13. Country-Wise Down Syndrome Market Analysis (2019–2032)

14. Down Syndrome Market Access and Reimbursement of Therapies

15. Down Syndrome Market Drivers

16. Down Syndrome Market Barriers

17.  Down Syndrome Appendix

18. Down Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Macular Edema, historical and forecasted epidemiology as well as the Diabetic Macular Edema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Diabetic Macular Edema, offering comprehensive insights into the Diabetic Macular Edema revenue trends, prevalence, and treatment landscape. The report delves into key Diabetic Macular Edema statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Diabetic Macular Edema therapies. Additionally, we cover the landscape of Diabetic Macular Edema clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Diabetic Macular Edema treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Diabetic Macular Edema space.

To Know in detail about the Diabetic Macular Edema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Macular Edema Market Forecast

Some of the key facts of the Diabetic Macular Edema Market Report: 

• The Diabetic Macular Edema market size was valued ~USD 2.9 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In 2022, the market size for diabetic macular edema (DME) across the United States, EU4 (Germany, Spain, Italy, France), the UK, and Japan was approximately USD 2,911 million.

• The market size is projected to grow during the forecast period (2023–2034) due to the introduction of upcoming therapies. In 2022, the United States held the largest market share, with an estimated size of approximately USD 1,745 million.

• Key Diabetic Macular Edema Companies: Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others

• Key Diabetic Macular Edema Therapies: OCS-01, THR-149, Ranibizumab, EXN407, IBE-814, EYP-1901, RC-28E, Aflibercept, Conbercept, CU06-1004, and others

• The Diabetic Macular Edema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Macular Edema pipeline products will significantly revolutionize the Diabetic Macular Edema market dynamics.

• DelveInsight’s analysis revealed that the total prevalent cases of diabetic macular edema (DME) in the 7MM reached 1,073,892 in 2022, with expectations of a significant compound annual growth rate (CAGR) throughout the study period.

• The United States had the highest number of diagnosed prevalent cases of diabetic macular edema (DME), estimated at approximately 483,251 in 2022, and is expected to see a significant increase at a compound annual growth rate (CAGR).

• The diagnosed prevalent cases of diabetic macular edema (DME) were classified into three age groups: 18-44 years, 45-64 years, and 75 years and older. In 2022, the age group of 45-64 years had the highest number of cases, totaling 209,740 in the US.

Diabetic Macular Edema Overview

Diabetic macular edema (DME) is a complication of diabetes that occurs when high blood sugar levels damage the blood vessels in the retina, leading to fluid leakage and swelling in the macula, the central part of the retina responsible for sharp vision. This condition can cause blurred or distorted vision and may result in significant vision loss if not treated. DME is often associated with diabetic retinopathy, and management may include controlling blood sugar levels, laser therapy, or injections of medications to reduce swelling and improve vision.

Get a Free sample for the Diabetic Macular Edema Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/diabetic-macular-edema-dme-market

Diabetic Macular Edema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Macular Edema Epidemiology Segmentation:

The Diabetic Macular Edema market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of DME in the 7MM

• Total Diagnosed Prevalent Cases of DME in the 7MM

• Gender-specific Diagnosed Prevalent Cases of DME in the 7MM

• Age-Specific Diagnosed Prevalent Cases of DME in the 7MM

• Subgroup-specific Diagnosed Prevalent Cases of DME in the 7MM

• Treated cases of DME in the 7MM

Download the report to understand which factors are driving Diabetic Macular Edema epidemiology trends @ Diabetic Macular Edema Epidemiology Forecast

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Macular Edema market or expected to get launched during the study period. The analysis covers Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Macular Edema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Macular Edema Therapies and Key Companies

• OCS-01: Oculis

• THR-149: Oxurion

• Ranibizumab: Novartis

• EXN407: Exonate Limited

• IBE-814: Ripple Therapeutics

• EYP-1901: EyePoint Pharmaceuticals

• RC-28E: RemeGen Co., Ltd.

• Aflibercept: Alimera Sciences

• Conbercept: RemeGen Co., Ltd.

• CU06-1004: Curacle Co., Ltd.

• Faricimab: Genentech, Inc.

Discover more about therapies set to grab major Diabetic Macular Edema market share @ Diabetic Macular Edema Treatment Landscape 

Diabetic Macular Edema Market Strengths

• Late-stage pipeline drugs such as Faricimab, Beovuand KSI-301 are some of the potential emerging therapies that have shown promising results and expected to improve the dosing interval

Diabetic Macular Edema Market Opportunities

• Around in one-quarter or more of eyes with center involving DME do not achieve complete resolution of the edema with anti-VEGF therapy and currently there is no curative treatment options for this refractory pool.

Scope of the Diabetic Macular Edema Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Diabetic Macular Edema Companies: Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharmaceuticals, RemeGen Co., Ltd., Alimera Sciences, Curacle Co., Ltd., Faricimab: Genentech, Inc., and others

• Key Diabetic Macular Edema Therapies: OCS-01, THR-149, Ranibizumab, EXN407, IBE-814, EYP-1901, RC-28E, Aflibercept, Conbercept, CU06-1004, and others

• Diabetic Macular Edema Therapeutic Assessment: Diabetic Macular Edema current marketed and Diabetic Macular Edema emerging therapies

• Diabetic Macular Edema Market Dynamics: Diabetic Macular Edema market drivers and Diabetic Macular Edema market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Diabetic Macular Edema Unmet Needs, KOL’s views, Analyst’s views, Diabetic Macular Edema Market Access and Reimbursement 

To know more about Diabetic Macular Edema companies working in the treatment market, visit @ Diabetic Macular Edema Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Diabetic Macular Edema Market Report Introduction

2. Executive Summary for Diabetic Macular Edema

3. SWOT analysis of Diabetic Macular Edema

4. Diabetic Macular Edema Patient Share (%) Overview at a Glance

5. Diabetic Macular Edema Market Overview at a Glance

6. Diabetic Macular Edema Disease Background and Overview

7. Diabetic Macular Edema Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Macular Edema 

9. Diabetic Macular Edema Current Treatment and Medical Practices

10. Diabetic Macular Edema Unmet Needs

11. Diabetic Macular Edema Emerging Therapies

12. Diabetic Macular Edema Market Outlook

13. Country-Wise Diabetic Macular Edema Market Analysis (2020–2034)

14. Diabetic Macular Edema Market Access and Reimbursement of Therapies

15. Diabetic Macular Edema Market Drivers

16. Diabetic Macular Edema Market Barriers

17.  Diabetic Macular Edema Appendix

18. Diabetic Macular Edema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Macular Edema Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Oculis, Oxurion, Novartis, Exonate Limited, Ripple Therapeutics, EyePoint Pharma, RemeGen